Jin Xun, Kim Leo J Y, Wu Qiulian, Wallace Lisa C, Prager Briana C, Sanvoranart Tanwarat, Gimple Ryan C, Wang Xiuxing, Mack Stephen C, Miller Tyler E, Huang Ping, Valentim Claudia L, Zhou Qi-Gang, Barnholtz-Sloan Jill S, Bao Shideng, Sloan Andrew E, Rich Jeremy N
Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Tianjin Medical University Cancer Institute and Hospital, Tianjin, P.R. China.
Nat Med. 2017 Nov;23(11):1352-1361. doi: 10.1038/nm.4415. Epub 2017 Oct 9.
Glioblastomas are lethal cancers defined by angiogenesis and pseudopalisading necrosis. Here, we demonstrate that these histological features are associated with distinct transcriptional programs, with vascular regions showing a proneural profile, and hypoxic regions showing a mesenchymal pattern. As these regions harbor glioma stem cells (GSCs), we investigated the epigenetic regulation of these two niches. Proneural, perivascular GSCs activated EZH2, whereas mesenchymal GSCs in hypoxic regions expressed BMI1 protein, which promoted cellular survival under stress due to downregulation of the E3 ligase RNF144A. Using both genetic and pharmacologic inhibition, we found that proneural GSCs are preferentially sensitive to EZH2 disruption, whereas mesenchymal GSCs are more sensitive to BMI1 inhibition. Given that glioblastomas contain both proneural and mesenchymal GSCs, combined EZH2 and BMI1 targeting proved more effective than either agent alone both in culture and in vivo, suggesting that strategies that simultaneously target multiple epigenetic regulators within glioblastomas may be effective in overcoming therapy resistance caused by intratumoral heterogeneity.
胶质母细胞瘤是由血管生成和假栅栏状坏死所定义的致命性癌症。在此,我们证明这些组织学特征与不同的转录程序相关,血管区域呈现神经前体细胞特征,而缺氧区域呈现间充质细胞模式。由于这些区域含有胶质瘤干细胞(GSCs),我们研究了这两个生态位的表观遗传调控。神经前体细胞样的血管周围GSCs激活EZH2,而缺氧区域的间充质GSCs表达BMI1蛋白,该蛋白通过下调E3连接酶RNF144A促进应激条件下的细胞存活。通过基因抑制和药物抑制,我们发现神经前体细胞样GSCs对EZH2破坏更敏感,而间充质GSCs对BMI1抑制更敏感。鉴于胶质母细胞瘤同时含有神经前体细胞样和间充质GSCs,在培养和体内实验中,联合靶向EZH2和BMI1比单独使用任何一种药物都更有效,这表明同时靶向胶质母细胞瘤内多种表观遗传调节因子的策略可能有效克服由肿瘤内异质性引起的治疗抗性。